Update shared on 11 Nov 2025
Fair value Decreased 1.98%Analysts have lowered their price target for Fresenius Medical Care from $49.03 to $48.06. They cite slight adjustments to projected discount rates and earnings multiples, even as improvements in revenue growth and profit margins are expected.
What's in the News
- The company completed the repurchase of 3,564,523 shares, representing 1.21% of share capital, for €151.78 million as part of a buyback program announced in June 2025 (Key Developments).
- The company issued an outlook for fiscal 2025 with projected positive to low-single digit percent revenue growth compared to the previous year (Key Developments).
- The company anticipates high-teens to high-twenties percent growth in operating income, excluding special items, for 2025 at constant currency (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has decreased slightly from $49.03 to $48.06.
- The discount rate has risen moderately from 5.05% to 5.21%.
- The revenue growth projection has improved slightly from 3.53% to 3.91%.
- The net profit margin expectation has increased marginally from 6.25% to 6.39%.
- The future P/E ratio has declined from 12.29x to 11.09x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.